The DOI matches its Crossref record; 34 of the 37 references it cites were found in a registry or an index.
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Open accessAbstract
Background Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer.Methods In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged ≥18 years) with histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MSI-H from 31 sites (academic centres and hospitals) in eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA). Eligible patients had progressed on or after, or been intolerant of, at least one previous line of treatment, including a fluoropyrimidine and oxaliplatin or irinotecan. Patients were given 3 mg/kg nivolumab every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study. The primary endpoint was investigator-assessed objective response as per Response Evaluation Criteria in Solid Tumors (version 1.1). All patients who received at least one dose of study drug were included in all analyses. This trial is registered with ClinicalTrials.gov, number NCT02060188.Findings Of the 74 patients who were enrolled between March 12, 2014, and March 16, 2016, 40 (54%) had received three or more previous treatments. At a median follow-up of 12·0 months (IQR 8·6-18·0), 23 (31·1%, 95% CI 20·8-42·9) of 74 patients achieved an investigator-assessed objective response and 51 (69%, 57-79) patients had disease control for 12 weeks or longer. Median duration of response was not yet reached; all responders were alive, and eight had responses lasting 12 months or longer (Kaplan-Meier 12-month estimate 86%, 95% CI 62-95). The most common grade 3 or 4 drug-related adverse events were increased concentrations of lipase (six [8%]) and amylase (two [3%]). 23 (31%) patients died during the study; none of these deaths were deemed to be treatment related by the investigator.Interpretation Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Initial results demonstrated a 31% objective response rate and 69% demonstrated at least 12 weeks of stable disease [78].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [78]
In the citing paper
“The Checkmate-142 phase II study demonstrated the effectiveness of nivolumab in previously treated MSI-H mCRC patients [84].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Upon examining the subgroup analysis of this study, it was observed that patients without RAS or BRAF mutations achieved a 41% objective response rate with nivolumab. In comparison, the rate was 27% in RAS mutant patients.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Additionally, the efficacy of ICIs in phase II studies with dMMR/MSI and BRAFV600E tumors versus dMMR/MSI and BRAF wild type was similar [53,54,55,56].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Recently, a combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, gained approval from the FDA for the treatment of previously treated MSI-H/dMMR mCRC [54,131].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Nivolumab, an anti-PD1 monoclonal antibody (moAb), has been utilized since 1 August 2017, for MSI-H/dMMR mCRC, as evidenced by the CheckMate 142 study [54].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“The CHECKMATE 142 study reported that Nivolumab could provide a durable response in patients with dMMR/MSI-H metastatic colorectal cancer, proposing Nivolumab as a new treatment option in these patients [117].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [117]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Cited by
Sorted by citations
Items 401–500 of 1,005
PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors
Duhen, R., Fesneau, O., Samson, K. A., Frye, A. K., Beymer, M., Rajamanickam, V., Ross, D., Tran, E., Bernard, B. M., Weinberg, A. D., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156821 · Cited by 79
Küçükköse, E., Heesters, B. A., Villaudy, J., Verheem, A., Cercel, M. G., van Hal, S., Boj, S. F., Rinkes, I. H. M. B., Punt, C. J. A., Roodhart, J. M. L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005345 · Cited by 74
Results and challenges of immune checkpoint inhibitors in colorectal cancer
Emambux, S., Tachon, G., Junca, A., & Tougeron, D. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1445222 · Cited by 74
New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors
de Morais, A. L. G., Cerdá, S. S., & Miguel, M. J. D. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01218-y · Cited by 73
Rupp, T., Genest, L., Babin, D., Legrand, C., Hunault, M., Froget, G., & Castagné, V. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101405 · Cited by 75
Gutierrez, C., Ogino, S., Meyerhardt, J. A., & Iorgulescu, J. B. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00179 · Cited by 74
Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update
Boukouris, A. E., Theochari, M., Stefanou, D. T., Papalambros, A., Felekouras, E. S., Gogas, H. J., & Ziogas, D. C. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103663 · Cited by 73
Computational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 79
Bins, S., Basak, E. A., Bouazzaoui, S. E., Koolen, S. L. W., Hoop, E. O., van der Leest, C. H., van der Veldt, A. A. M., Sleijfer, S., Debets, R., van Schaik, R. H. N., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0074-1 · Cited by 70
Colle, R., Radzik, A., Cohen, R., Pellat, A., López‐Trabada, D., Cachanado, M., Duval, A., Svrcek, M., Menu, Y., & André, T. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.009 · Cited by 70
Self-citationGinghină, O., Hudiță, A., Zamfir, M., Spânu, A., Mardare, M., Bondoc, I., Buburuzan, L., Georgescu, S. E., Costache, M., Negrei, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.856575 · Cited by 78
Aran, A., Garrigós, L., Curigliano, G., Cortés, J., & Martı́, M. (2022) · Cancers · doi:10.3390/cancers14071771 · Cited by 72
Immunotherapy in endometrial cancer
Mahdi, H., Chelariu-Raicu, A., & Slomovitz, B. M. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003675 · Cited by 85
Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers
Inthagard, J., Edwards, J., & Roseweir, A. K. (2019) · Clinical Science · doi:10.1042/cs20181003 · Cited by 70
Shevtsov, M. A., Pitkin, E., Ischenko, A. M., Stangl, S., Khachatryan, W. А., Galibin, O. V., Edmond, S., Lobinger, D., & Multhoff, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00454 · Cited by 69
Therapeutic Targeting of the Colorectal Tumor Stroma
Fridman, W. H., Miller, I. S., Sautès‐Fridman, C., & Byrne, A. T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.045 · Cited by 72
Gudd, C. L. C., Au, L., Triantafyllou, E., Shum, B., Liu, T., Nathwani, R., Kumar, N., Mukherjee, S. K., Dhar, A., Woollard, K. J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.008 · Cited by 69
Ratovomanana, T., Cohen, R., Svrcek, M., Renaud, F., Cervera, P., Siret, A., Letourneur, Q., Buhard, O., Bourgoin, P., Guillerm, E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.05.007 · Cited by 68
Self-citationWang, E., Xiang, K., Zhang, Y., & Wang, X.-F. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.001 · Cited by 56
Chen, Y., Chen, M., & Deng, K. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5472 · Cited by 69
The Tumor Microenvironment in Colorectal Cancer Therapy
Pedrosa, L., Esposito, F. M., Thomson, T. M., & Maurel, J. (2019) · Cancers · doi:10.3390/cancers11081172 · Cited by 73
Multi-omics Approach Reveals Distinct Differences in Left- and Right-Sided Colon Cancer
Hu, W., Yang, Y., Li, X., Huang, M., Xu, F., Ge, W., Zhang, S., & Zheng, S. S. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0483 · Cited by 68
Kreidieh, M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · BioMed Research International · doi:10.1155/2020/9037217 · Cited by 68
Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel
Yu, Z., Li, X., Duan, J., & Yang, X. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s267177 · Cited by 70
Zou, Q., Wang, X.-L., Ren, D., Hu, B., Tang, G.-N., Zhang, Y., Huang, M.-J., Pai, R., Buchanan, D., Win, A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002671 · Cited by 60
Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 73
Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
Decraene, B., Yang, Y., Smet, F. D., Garg, A. D., Agostinis, P., & Vleeschouwer, S. D. (2022) · Genes and Immunity · doi:10.1038/s41435-021-00161-5 · Cited by 75
Porcellini, E., Laprovitera, N., Riefolo, M., Ravaioli, M., Garajova, I., & Ferracin, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.049 · Cited by 66
Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer
Jin, Z., & Sinicrope, F. A. (2021) · Cancers · doi:10.3390/cancers13020300 · Cited by 67
Stein, A., Simnica, D., Schultheiß, C., Scholz, R., Tintelnot, J., Goekkurt, E., von Wenserski, L., Willscher, E., Paschold, L., Sauer, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002844 · Cited by 66
Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications
Wang, D.-K., Zuo, Q., He, Q., & Li, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705999 · Cited by 69
Ouyang, H., Xiao, B., Huang, Y., & Wang, Z. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110703 · Cited by 70
Cai, L., Chen, A., & Tang, D. (2024) · Immunology · doi:10.1111/imm.13785 · Cited by 73
From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Osipov, A., Murphy, A. G., & Zheng, L. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.002 · Cited by 69
Lau, D. K., Kalaitzaki, E., Church, D. N., Pandha, H., Tomlinson, I. P. M., Annels, N. E., Gerlinger, M., Sclafani, F., Smith, G. A., Begum, R., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000638 · Cited by 67
Stopfer, L. E., Flower, C. T., Gajadhar, A. S., Patel, B., Gallien, S., López‐Ferrer, D., & White, F. M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3804 · Cited by 67
Gilson, P., Merlin, J., & Harlé, A. (2021) · Cancers · doi:10.3390/cancers13071491 · Cited by 65
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Hollebecque, A., Chung, H. C., de Miguel, M. J., Italiano, A., Machiels, J.-P., Lin, C.-C., Dhani, N. C., Peeters, M., Moreno, V., Su, W.-C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0261 · Cited by 65
Randrian, V., Evrard, C., & Tougeron, D. (2021) · Cancers · doi:10.3390/cancers13123063 · Cited by 65
Ieranò, C., Righelli, D., D’Alterio, C., Napolitano, M., Portella, L., Rea, G., Auletta, F., Santagata, S., Trotta, A. M., Guardascione, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004032 · Cited by 65
Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
Carlsen, L., Huntington, K. E., & El‐Deiry, W. S. (2022) · Cancers · doi:10.3390/cancers14041028 · Cited by 67
Papke, D. J., Nowak, J. A., Yurgelun, M. B. B., Frieden, A., Srivastava, A., Lindeman, N. I., Sholl, L. M., MacConaill, L. E., & Dong, F. (2018) · Modern Pathology · doi:10.1038/s41379-018-0091-x · Cited by 66
Pedersen, K. S., Foster, N. R., Overman, M. J., Boland, P. M., Kim, S. S., Arrambide, K. A., Jaszewski, B. L., Bekaii‐Saab, T., Graham, R. P., Welch, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0159 · Cited by 68
Self-citationZiogas, I. A., Evangeliou, A. P., Giannis, D., Hayat, M. H., Mylonas, K. S., Tohme, S. T., Geller, D. A., Elias, N., Goyal, L., & Tsoulfas, G. (2020) · The Oncologist · doi:10.1002/onco.13638 · Cited by 63
Huyghe, N. D., Benidovskaya, E., Stevens, P., & den Eynde, M. V. (2022) · Cancers · doi:10.3390/cancers14092241 · Cited by 65
Luo, D. Y., Zhou, J., Ruan, S., Zhang, B., Zhu, H., Que, Y., Ying, S., Li, X., Hu, Y., & Song, Z. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07385-7 · Cited by 73
Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes
Peiró, I., Palmero, R., Iglesias, P., Díez, J. J., Simó-Servat, A., Marín‐Jiménez, J. A., Jiménez, L., Domingo‐Doménech, E., Mancho-Fora, N., Nadal, E., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01871-7 · Cited by 63
Lü, J., Li, L., Lan, Y., Liang, Y., & Meng, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2661 · Cited by 63
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 61
Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice
Fassan, M., Scarpa, A., Remo, A., Maglio, G. D., Troncone, G., Marchetti, A., Doglioni, C., Ingravallo, G., Perrone, G., Parente, P., et al. (2020) · Pathologica · doi:10.32074/1591-951x-158 · Cited by 64
Colorectal cancer vaccines: The current scenario and future prospects
Jia, W., Zhang, T., Huang, H., Feng, H., Wang, S., Guo, Z., Luo, Z., Ji, X., Cheng, X., & Zhao, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.942235 · Cited by 62
Chen, K., Wang, Q., Liu, X., Tian, X., Dong, A., & Yang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04051-4 · Cited by 69
Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma
Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57
Gorbet, M.-J., & Ranjan, A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107456 · Cited by 64
Kawazoe, A., Yamaguchi, K., Yasui, H., Negoro, Y., Azuma, M., Amagai, K., Hara, H., Baba, H., Tsuda, M., Hosaka, H., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.002 · Cited by 62
Cancer immunotherapy: the art of targeting the tumor immune microenvironment
da Silva, J. L., dos Santos, A. L. S., Nunes, N. C. C., da Silva, F. D. M. L., Ferreira, C. G., & de Melo, A. C. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03894-3 · Cited by 62
Zhang, J., Cai, J. Q., Deng, Y., & Wang, H. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1663108 · Cited by 61
Kim, J. H., Kim, S. Y., Baek, J. Y., Jun, Y., Ahn, J. B., Kim, H. S., Lee, K., Kim, J., Kim, T., Chang, W. J., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.218 · Cited by 62
Current Microsatellite Instability Testing in Management of Colorectal Cancer
Sun, B. L. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.08.001 · Cited by 66
Ragoonanan, D. S., Khazal, S. J., Abdel‐Azim, H., McCall, D. C., Cuglievan, B., Tambaro, F. P., Ahmad, A. H., Rowan, C. M., Gutiérrez, C., Schadler, K., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00474-4 · Cited by 62
André, T., Cohen, R., & Salem, M. E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349557 · Cited by 63
Self-citationKovacs, S., & Győrffy, B. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03409-4 · Cited by 58
Martínez-Ordóñez, A., Durán, Á., Ruíz-Martínez, M., Cid-Diaz, T., Zhang, X., Han, Q., Kinoshita, H., Muta, Y., Linares, J. F., Kasashima, H., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.016 · Cited by 62
Kayhanian, H., Goode, E., Sclafani, F., Ang, J. E., Gerlinger, M., de Castro, D. G., Shepherd, S. T. C., Peckitt, C., Rao, S., Watkins, D. J., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.006 · Cited by 61
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
Gómez‐España, M. A., Gallego-Plazas, J., González‐Flores, E., Maurel, J., Páez, D., Sastre, J., Aparicio, J., Benavides, M., Feliú, J., & Vera, R. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02002-w · Cited by 62
Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications
Cao, Q., Tian, Y., Deng, Z., Yang, F., & Chen, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063358 · Cited by 60
Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed
Pfohl, U., Pflaume, A., Regenbrecht, M., Finkler, S., Adelmann, Q. G., Reinhard, C., Regenbrecht, C. R. A., & Wedeken, L. (2021) · Cells · doi:10.3390/cells10040928 · Cited by 68
Hashimoto, M., Kojima, Y., Sakamoto, T., Ozato, Y., Nakano, Y., Abe, T., Hosoda, K., Saito, H., Higuchi, S., Hisamatsu, Y., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105102 · Cited by 66
Chae, Y. K., Anker, J. F., Bais, P., Namburi, S., Giles, F. J., & Chuang, J. H. (2017) · Oncotarget · doi:10.18632/oncotarget.23742 · Cited by 65
Nivolumab in the Treatment of Microsatellite Instability High Metastatic Colorectal Cancer
Sarshekeh, A. M., Overman, M. J., & Kopetz, S. (2018) · Future Oncology · doi:10.2217/fon-2017-0696 · Cited by 60
Self-citationUpdate in version 2021 of CSCO guidelines for colorectal cancer from version 2020
Dong, C., Ding, Y., Weng, S., Li, G., Huang, Y., Hu, H., Zhang, Z., Zhang, S., & Yuan, Y. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.03.02 · Cited by 60
Wang, Y., Ding, Y., Deng, Y., Zheng, Y., & Wang, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000609 · Cited by 59
Current status and perspectives of immune checkpoint inhibitors for colorectal cancer
Hirano, H., Takashima, A., Hamaguchi, T., Shida, D., & Kanemitsu, Y. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa200 · Cited by 63
Pan, Y., Fu, Y., Zeng, Y., Liu, X., Peng, Y., Hu, C., Deng, C., Qiu, Z., Zou, J. P., Liu, Y., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00355-7 · Cited by 57
Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
Zhou, Q., Peng, Y., Ji, F., Chen, H., Kang, W., Chan, L.-S., Gou, H., Lin, Y., Huang, P., Chen, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39571-6 · Cited by 63
Overman, M. J., Gelsomino, F., Aglietta, M., Wong, M. K., Mirón, M. L. L., Leonard, G., Alfonso, P. G., Hill, A. G., Gracián, A. C., Cutsem, E. V., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008689 · Cited by 63
Self-citationMandal, K., Barik, G. K., & Santra, M. K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02400-z · Cited by 69
Hamada, T., Soong, T. R., Masugi, Y., Kosumi, K., Nowak, J. A., da Silva, A., Mu, X. J., Twombly, T. S., Koh, H., Yang, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442999 · Cited by 60
Wang, L., Zhang, Q., Ni, S., Tan, C., Cai, X., Huang, D., & Sheng, W. (2018) · Cancer Medicine · doi:10.1002/cam4.1502 · Cited by 59
Drug response to PD-1/PD-L1 blockade: based on biomarkers
Chen, Q., Li, T., & Yue, W. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s168313 · Cited by 59
Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches
Tintelnot, J., & Stein, A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3920 · Cited by 59
DNA methylation and chromatin modifiers in colorectal cancer
Vymetalkova, V. P., Vodička, P., Vodenková, S., Alonso, S., & Schneider‐Stock, R. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.04.002 · Cited by 58
Ratovomanana, T., Nicolle, R., Cohen, R., Diehl, A., Siret, A., Letourneur, Q., Buhard, O., Perrier, A., Guillerm, E., Coulet, F., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.010 · Cited by 59
Self-citationAlmawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
Evolving neoantigen profiles in colorectal cancers with DNA repair defects
Rospo, G., Lorenzato, A., Amirouchene-Angelozzi, N., Magrì, A., Cancelliere, C., Corti, G., Negrino, C., Amodio, V., Montone, M., Bartolini, A., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0654-6 · Cited by 58
Methylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57
DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers
Bañobre, J. R., & Goel, A. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.11.071 · Cited by 58
Shimizu, T., Miyake, M., Hori, S., Ichikawa, K., Omori, C., Iemura, Y., Owari, T., Itami, Y., Nakai, Y., Anai, S., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10050310 · Cited by 59
Gut microbiota: impacts on gastrointestinal cancer immunotherapy
Lau, H. C.-H., Sung, J. J. �., & Yu, J. Q. (2021) · Gut Microbes · doi:10.1080/19490976.2020.1869504 · Cited by 58
Xu, M., Mu, J., Wang, J., Zhou, Q., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961213 · Cited by 56
Li, Q., Zhang, C., Xu, G., Shang, X., Nan, X., Li, Y., Liu, J., Hong, Y., Wang, Q., & Peng, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116172 · Cited by 57
Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors
Puccini, A., Lenz, H., Marshall, J. L., Arguello, D., Raghavan, D., Korn, W. M., Weinberg, B. A., Poorman, K. A., Heeke, A. L., Philip, P. A., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0117 · Cited by 60
Self-citationPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 59
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
Marmorino, F., Boccaccino, A., Germani, M. M., Falcone, A., & Cremolini, C. (2020) · Cancers · doi:10.3390/cancers12082317 · Cited by 58
The Landscape of Actionable Gene Fusions in Colorectal Cancer
Pagani, F., Randon, G., Guarini, V., Raimondi, A., Prisciandaro, M., Lobefaro, R., Bartolomeo, M. D., Sozzi, G., de Braud, F., Gasparini, P., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215319 · Cited by 58
The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer
Body, A. L., Prenen, H., Latham, S., Lam, M., Tipping-Smith, S., Raghunath, A., & Segelov, E. (2021) · Cancer Management and Research · doi:10.2147/cmar.s262870 · Cited by 58
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 58
Yang, Z., Wu, G., Zhang, X., Gao, J., Meng, C., Liu, Y., Wei, Q., Sun, L., Wei, P., Bai, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001444 · Cited by 56
Metadata
- Authors
- Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., Goldberg, M. V., Cao, Z. A., Ledeine, J.-M., Maglinte, G. A., Kopetz, S., & André, T.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Cancer Trials Ireland (IE)
- Allina Health (US)
- Istituto Oncologico Veneto (IT)
- USC Norris Comprehensive Cancer Center (US)
- Duke Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (Belgium) (BE)
- Sorbonne Université (FR)
- Corresponding author
- Overman, Michael J
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 18
- Issue
- 9
- Pages
- 1182-1191
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC6207072
- OpenAlex
- W2739132742
- Cited by
- 2,836
- References
- 37
- Citations by year
- 2026: 185 · 2025: 242 · 2024: 302 · 2023: 382 · 2022: 377 · 2021: 438 · 2020: 361 · 2019: 288 · 2018: 223 · 2017: 31
- FWCI
- 108.88
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-09-01)
- Open access
- green
- europepmc.org
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- National Institutes of Health (UL1TR000371)
- National Cancer Institute (P30CA016672)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- nivolumab, metastatic colorectal cancer, mismatch repair deficiency, microsatellite instability-high, PD-1 inhibitors, immune checkpoint blockade, objective response rate, disease control rate, progression-free survival, overall survival, treatment toxicity, first-line therapy, second-line therapy, third-line therapy, neoantigens, tumor-infiltrating lymphocytes
- MeSH terms
- Nivolumab, Adult, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Female, Humans, Male, Middle Aged, Colorectal Neoplasms, Treatment Outcome, Disease-Free Survival, Microsatellite Instability, DNA Mismatch Repair, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
